ES2600081T3 - Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII - Google Patents

Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII Download PDF

Info

Publication number
ES2600081T3
ES2600081T3 ES12777895.9T ES12777895T ES2600081T3 ES 2600081 T3 ES2600081 T3 ES 2600081T3 ES 12777895 T ES12777895 T ES 12777895T ES 2600081 T3 ES2600081 T3 ES 2600081T3
Authority
ES
Spain
Prior art keywords
factor viii
body weight
approximately
fviii
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12777895.9T
Other languages
English (en)
Spanish (es)
Inventor
Hubert. METZNER
Sabine. ZOLLNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2600081T3 publication Critical patent/ES2600081T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES12777895.9T 2011-10-18 2012-10-18 Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII Active ES2600081T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548606P 2011-10-18 2011-10-18
EP11185648 2011-10-18
US201161548606P 2011-10-18
EP11185648 2011-10-18
PCT/EP2012/070615 WO2013057167A1 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii

Publications (1)

Publication Number Publication Date
ES2600081T3 true ES2600081T3 (es) 2017-02-07

Family

ID=48140372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12777895.9T Active ES2600081T3 (es) 2011-10-18 2012-10-18 Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII

Country Status (10)

Country Link
US (1) US9393289B2 (https=)
EP (1) EP2768522B1 (https=)
JP (1) JP6072810B2 (https=)
KR (1) KR20140083036A (https=)
CN (1) CN103889445A (https=)
AU (1) AU2012318279B2 (https=)
CA (1) CA2852397A1 (https=)
DK (1) DK2768522T3 (https=)
ES (1) ES2600081T3 (https=)
WO (1) WO2013057167A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6029674B2 (ja) 2011-10-18 2016-11-24 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
AU2015270394B2 (en) 2014-06-06 2017-12-21 Octapharma Ag Preparation comprising Factor VIII and Von Willebrand factor peptides
JP6730260B2 (ja) * 2014-09-12 2020-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬
MX388739B (es) 2015-02-06 2025-03-20 Univ North Carolina Chapel Hill Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
WO1997040145A1 (en) 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
CA2450125A1 (en) 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
PL2257311T3 (pl) * 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Also Published As

Publication number Publication date
KR20140083036A (ko) 2014-07-03
US9393289B2 (en) 2016-07-19
CN103889445A (zh) 2014-06-25
AU2012318279B2 (en) 2015-06-04
WO2013057167A1 (en) 2013-04-25
CA2852397A1 (en) 2013-04-25
JP6072810B2 (ja) 2017-02-01
DK2768522T3 (en) 2016-11-14
US20140315815A1 (en) 2014-10-23
EP2768522A1 (en) 2014-08-27
EP2768522B1 (en) 2016-07-27
AU2012318279A1 (en) 2013-05-02
JP2014530246A (ja) 2014-11-17

Similar Documents

Publication Publication Date Title
US11510968B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
ES2392569T3 (es) Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
ES2600081T3 (es) Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
JP6029674B2 (ja) 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
HK1197648B (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197648A (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197649B (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii